Is molecular profiling for gynaecological cancers worth the cost?
In this era of precision medicine, affordable profiling is essential
Managing ovarian cancer in the PARP inhibitor era
The role of PARP inhibitors features in a number of sessions at the ESMO Gynaecological Cancers Congress 2022
Can academic oncology compete with the career prospects offered by the pharma industry?
Moving back and forth across academic and corporate positions has become increasingly common for oncologists in search of new opportunities
De-escalation of cancer treatments may be key to sustainability in oncology
Treating patients at reduced doses could contribute to a more efficient allocation of healthcare resources and improve access to costly treatments around the world, but implementation of de-escalation in routine practice requires reliable and cost-effective tools to safely tailor therapy to patients
Cancer treatment – how to wisely reduce its burden? A new ESMO tool to guide de-intensification
ESMO developed a classification to assess the risk-benefit ratio of treatment intensity modulation by a three-tiered approach
How to discuss cancer treatment modulation with patients?
Experience in breast cancer shows that treatment de-intensification must follow robust evidence, but also values and preferences to generate acceptance
Results suggest the efficacy of trastuzumab deruxtecan is influenced by the spatial distribution of HER2 in breast tumour cells
A translational analysis of the DAISY trial improves knowledge on the mechanisms of action of the antibody–drug conjugate
Interim analysis shows that the safety of sacituzumab govitecan is in line with expectations
In the SASCIA trial, sacituzumab govitecan was associated with a higher incidence of adverse events and dose delays than treatment of physician’s choice in patients with HER2-negative breast cancer at high risk of relapse, but dose reductions occurred with a similar frequency in both arms
Combining PARP1 inhibition with an ATR inhibitor does not improve outcomes in pre-treated metastatic TNBC
Results from the VIOLETTE trial also suggest that mutation status may influence response to each agent
Do CDK4/6 inhibitors affect fertility and are they beneficial in premenopausal women?
Two studies hint at a lack of effect of palbociclib on ovarian function and demonstrate similar reduced recurrence with abemaciclib regardless of menopausal status